CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC belantamab mafodotin, pomalidomide, dexamethasone Previously treated multiple myeloma Pending
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Suspended
TBC rozanolixizumab Generalized myasthenia gravis (gMG) Active
TBC omaveloxolone Friedreich’s ataxia Active
TBC crovalimab paroxysmal nocturnal hemoglobinuria (PNH) Active
TBC zolbetuximab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
TBC delgocitinib Chronic hand eczema Pending
TBC dabrafenib-trametinib Pediatric low grade glioma (ped LGG) Active
TBC elafibranor Primary biliary cholangitis (PBC) Pending
TBC cipaglucosidase alfa and miglustat Pompe disease Pending
TBC donanemab Alzheimer's disease Active
TBC Darunavir / cobicistat HIV infection Withdrawn
TBC Efanesoctocog alfa congenital factor VIII deficiency Active
TBC garadacimab Hereditary angioedema (HAE) Active
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Active
TBC momelotinib Myelofibrosis Active
TBC fecal microbiota Clostridioides difficile infection, prevention Pending
TBC datopotamab deruxtecan advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC) Cancelled
TBC teprotumumab Thyroid Eye Disease (TED), chronic Active
TBC teprotumumab Thyroid Eye Disease (TED), acute Active
TBC nemolizumab Prurigo nodularis (PN) Pending
TBD Cabozantinib Withdrawn
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
TBD Entrectinib Withdrawn
Last Updated : November 22, 2024